Literature DB >> 7645203

Murray valley encephalitis virus envelope protein antigenic variants with altered hemagglutination properties and reduced neuroinvasiveness in mice.

P C McMinn1, E Lee, S Hartley, J T Roehrig, L Dalgarno, R C Weir.   

Abstract

Neutralization escape variants of Murray Valley encephalitis virus were selected using a type-specific, neutralizing, and passively protective anti-envelope protein (E) monoclonal antibody (4B6C-2) which defines epitope E-1c. Nucleotide sequence analysis revealed single nucleotide changes in the E genes of 15 variants resulting in nonconservative amino acid substitutions in all cases. One variant had a three-nucleotide deletion in the E gene which resulted in loss of serine at residue 277. Changes were clustered into two separate regions of the E polypeptide (residues 126-128 and 274-277), indicating that E-1c is a discontinuous epitope. One variant (BHv1), altered at residue 277 (Ser-->Ile), failed to hemagglutinate across the pH range 5.5-7.5, in contrast to parental virus and the other escape variants which hemagglutinated at an optimal pH of 6.6. BHv1 was also of reduced neuroinvasiveness in 21-day-old mice following intraperitoneal inoculation compared to the other viruses. Parental virus and the neutralization escape variants grew equally well in both vertebrate and invertebrate cell cultures, indicating that the reduced neuroinvasiveness of BHv1 was not due to a major abnormality of replication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645203     DOI: 10.1006/viro.1995.1374

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains.

Authors:  David W C Beasley; Melissa C Whiteman; Shuliu Zhang; Claire Y-H Huang; Bradley S Schneider; Darci R Smith; Gregory D Gromowski; Stephen Higgs; Richard M Kinney; Alan D T Barrett
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

Authors:  J Arroyo; F Guirakhoo; S Fenner; Z X Zhang; T P Monath; T J Chambers
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

Authors:  Ruklanthi de Alwis; Scott A Smith; Nicholas P Olivarez; William B Messer; Jeremy P Huynh; Wahala M P B Wahala; Laura J White; Michael S Diamond; Ralph S Baric; James E Crowe; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-12       Impact factor: 11.205

5.  Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread.

Authors:  Leonsia A Vlaycheva; Thomas J Chambers
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.

Authors:  Matthew R Vogt; Bastiaan Moesker; Jaap Goudsmit; Mandy Jongeneelen; S Kyle Austin; Theodore Oliphant; Steevenson Nelson; Theodore C Pierson; Jan Wilschut; Mark Throsby; Michael S Diamond
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

8.  Genetic and phenotypic differences between isolates of Murray Valley encephalitis virus in Western Australia, 1972-2003.

Authors:  Cheryl A Johansen; Veronica Susai; Roy A Hall; John S Mackenzie; David C Clark; Fiona J May; Stéphane Hemmerter; David W Smith; Annette K Broom
Journal:  Virus Genes       Date:  2007-03-29       Impact factor: 2.332

9.  Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.

Authors:  Ana P Goncalvez; Cheng-Hsin Chien; Kamolchanok Tubthong; Inna Gorshkova; Carrie Roll; Olivia Donau; Peter Schuck; Sutee Yoksan; Sy-Dar Wang; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model.

Authors:  Janice Nickells; Maria Cannella; Deborah A Droll; Yan Liang; William S M Wold; Thomas J Chambers
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.